Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03387176 · ClinicalTrials.gov registry record

Efficacy of a Gluten-free Diet in Difficult to Manage Nephrotic Syndrome: Utility of Plasma Zonulin Levels as a Predictive Biomarker

A clinical trial, sponsored by NYU Langone Health.

Completed
Registry status
13
Enrollment target

NCT03387176: Completed study, sponsored by NYU Langone Health.

NCT03387176 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03387176 has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
13 participants
Enrollment target

Study Summary

Elevated plasma zonulin levels, which are supportive of a diagnosis of CD (celiac disease) in children with gastrointestinal symptoms, may indicate patients with difficult-to-manage NS who will benefit from initiation of a GFD (gluten free diet). This pilot study will determine whether high plasma zonulin levels can be used as a screening tool to identify patients with NS (nephrotic syndrome) who are likely to demonstrate a beneficial response to a GFD. It will provide important information about the feasibility of testing the efficacy of a GFD for this condition and assist in the design and sample size calculation for a definitive trial to test the beneficial effect of this dietary intervention. Although NS is a rare condition in childhood, it is a chronic disease that can lead to short- and long-term disability especially in those with difficult-to-manage disease. There is an urgent need to develop safe and effective new therapies in this subgroup. This project may indicate the utility of a common dietary modification, a GFD, to treat these patients. The growing medical use of and greater access to gluten-free food items underscore the feasibility and timeliness of this approach.

Primary Outcome

Response is defined as a ≥50%decrease in relapse rate

Interventions

  • OTHER Implementation of a gluten-free diet

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2017-12-01
Est. Completion 2021-06-14
NYU Langone Health

1,164 total trials

What the finished NCT03387176 record still lists

NCT03387176 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Implementation of a gluten-free diet is the first listed.

NCT03387176 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03387176 about?

NCT03387176 is a clinical study titled "Efficacy of a Gluten-free Diet in Difficult to Manage Nephrotic Syndrome: Utility of Plasma Zonulin Levels as a Predictive Biomarker". Elevated plasma zonulin levels, which are supportive of a diagnosis of CD (celiac disease) in children with gastrointestinal symptoms, may indicate patients with difficult-to-manage NS who will benefit from initiation of a GFD (gluten free diet). This pilot study will determine whether high plasma z...

What is the current status of trial NCT03387176?

This trial is currently completed. The enrollment target is 13 participants. The study started on 2017-12-01. Estimated completion is 2021-06-14.

What interventions are being tested in trial NCT03387176?

The interventions under investigation include: Implementation of a gluten-free diet (OTHER).

Who is sponsoring clinical trial NCT03387176?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03387176, the US trial registry maintained by the National Library of Medicine. NCT03387176 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.